The company, with headquarters in Lod, specializes in glicomecanica which is the behavior of the Glycans, the sugars present in the surface of the cell membrane. Genes give instructions to proteins, but are the Glycans which guide to proteins to their objectives and make sure to do what they have to do. We have identified a specific antibody, which passed to the action when a foreign organism enters the body, and show up at levels higher in persons with multiple sclerosis explains Dukler. Tests showed that it is not a common denominator to all who suffer neural disorders, but it is specific of multiple sclerosis. The more active forms of multiple sclerosis have much higher concentrations of this antibody than in other less active forms of the disease. This is known as a biomarker of a specific disease.
A simple blood test using the MS GlycoChip’s Glycominds, a microscope the size of a biochip to test the reactions of the Glycans with other molecules, measured the level of this antibody and can help doctors prescribe the treatment, if this is necessary. The doctor takes a blood sample using the Glycominds kit, and then sends it to a laboratory for further analysis. Glycominds complete protocols of blood clinical trials of 80 centers in multiple sclerosis of United States, Canada and Israel. Trials that are about to begin the first days of 2005, 385 patients include, and it will be the greatest test never conducted with patients of CIS. In recent months, McDougall Program has been very successful. After spending the first year recruiting participants, the test will consist of multiple Windows of six months each. We predeciremos, taking blood tests in the first presentation of symptoms explained Dukler. This should reduce the anxiety of patients and allow doctors to take decisions concerning the most appropriate treatment. If blood tests predict that there will be no symptoms in the next six months, the doctor can alert the patient do not start taking the medication still.
After six months, the doctor performs another test. The trial is scheduled to continue until 2008. If, however, all goes according to plan and the results after the first period of six months, in 2006, they demonstrate that the blood test is in fact accurate, Glycominds will launch to market the product. The multiple sclerosis market is estimated at about $ 4 billion, highlights Dukler. Glycominds does not limit its efforts to multiple sclerosis and is also trying to develop biomarkers that allow a more accurate diagnosis of lumbar inflammatory disease, which affects about a million people in United States only. Within this category of Gycominds projects are Crohn’s disease and ulcerative colitis, of very similar symptoms, but which require completely different treatments: surgery can be used to treat ulcerative colitis, but poses many risks to a patient of Crohn’s disease. Glycominds also tries to expand the field. The Glycochip platform is the ability to identify many other biomarkers, observes Dukler. Inflammatory diseases and auto-immune disorders such as multiple sclerosis are the first step of the company, but it is not limited to this.